- Sanquin Reagents produces and sells blood group and immune reagents
- Gilde Healthcare’s investment will allow Sanquin Reagents to scale up the production of diagnostic tests, the firms said
- Sanguin will look to add to its research team with Gilde’s backing
Gilde Healthcare has announced its intention to buy Sanquin Reagents, a producer and seller of blood group and immune reagents. Gilde Healthcare’s investment will allow Sanquin Reagents to scale up the production of diagnostic tests and grow its research team, the firms said.
“We invest in companies that enable better healthcare at lower cost,” said Hugo de Bruin, partner at Gilde Healthcare. “Sanquin Reagents’ strong R&D focus on developing new reagents fits with this investment philosophy. We see ample opportunity to expand the unique research and production capabilities and develop new reagents.”
The deal for Amsterdam-based Sanquin Reagents is the first investment of Gilde’s €517 million Private Equity Fund IV.
Sanquin Health Solutions (SHS) is the seller.
“Sanquin Reagents has been able to develop well within Sanquin’s network over the past few years,” said Pieter de Geus, managing director of SHS. “There is a great product line, a solid organisation, and an incredible amount of knowledge and potential for new products. Under Gilde’s wing, Sanquin Reagents will certainly be able to grow and make even more of an impact. Patients worldwide will benefit from this.”
Utrecht-based Gilde Healthcare is a specialised healthcare investor. The Dutch investor manages €1.4 billion across two funds: one for private equity and one for venture/growth. The Private Equity Fund looks for lower mid-market healthcare companies based in North-Western Europe. It targets healthcare providers and suppliers of medical products and services.